Physician Perspectives 2017: Use of ustekinumab in IBD
Summary
This Physician Perspectives survey focuses on the use of ustekinumab in IBD.
UST appears to be the preferred nonTNF biologic for treatment of moderatetosevere Crohn's disease, most frequently prescribed after the failure of one or two antiTNFs most often IFX ADA, and before VDZ.
73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.
Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with leftsided UC, nonacute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.
The report includes following topics
Current clinical use of UST
UST safety efficacy
UST patient monitoring
Treatment response to UST
UST treatment strategies
Future use in UC.
Scope
Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
Physicians interviewed were from 5EU and US countries
This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.
Reasons to buy
Qualitative insight from 100 highprescribing specialists in IBD
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.